

	Derivation Cohort (N=698)	Validation Cohort (N=533)	Overall (N=1231)
Age			
<=72	379 (54.3%)	319 (59.9%)	698 (56.7%)
73-84	228 (32.7%)	143 (26.8%)	371 (30.1%)
>=85	91 (13.0%)	71 (13.3%)	162 (13.2%)
Sex			
Male	199 (28.5%)	167 (31.3%)	366 (29.7%)
Female	499 (71.5%)	366 (68.7%)	865 (70.3%)
Race			
White	525 (75.2%)	372 (69.8%)	897 (72.9%)
Black	81 (11.6%)	79 (14.8%)	160 (13.0%)
Others	92 (13.2%)	82 (15.4%)	174 (14.1%)
Tumor Size			
<=12	142 (20.3%)	101 (18.9%)	243 (19.7%)
13-40	426 (61.0%)	323 (60.6%)	749 (60.8%)
>=41	130 (18.6%)	109 (20.5%)	239 (19.4%)
Grade			
Well Differentiated	148 (21.2%)	111 (20.8%)	259 (21.0%)
Moderately Differentiated	342 (49.0%)	279 (52.3%)	621 (50.4%)
Poorly Differentiated	208 (29.8%)	143 (26.8%)	351 (28.5%)
AJCC Stage			
I	145 (20.8%)	85 (15.9%)	230 (18.7%)
II	406 (58.2%)	329 (61.7%)	735 (59.7%)
IIIB	141 (20.2%)	109 (20.5%)	250 (20.3%)
IVB	6 (0.9%)	10 (1.9%)	16 (1.3%)
T Stage			
T1a	50 (7.2%)	27 (5.1%)	77 (6.3%)
T1b	97 (13.9%)	69 (12.9%)	166 (13.5%)
T2	551 (78.9%)	437 (82.0%)	988 (80.3%)
Regional Nodes Positive			
0	556 (79.7%)	419 (78.6%)	975 (79.2%)
1-3	128 (18.3%)	110 (20.6%)	238 (19.3%)
>=4	14 (2.0%)	4 (0.8%)	18 (1.5%)
Radiotherapy after Surgery			
No	582 (83.4%)	464 (87.1%)	1046 (85.0%)
Yes	116 (16.6%)	69 (12.9%)	185 (15.0%)
Chemotherapy after Surgery			
No	502 (71.9%)	323 (60.6%)	825 (67.0%)
Yes	196 (28.1%)	210 (39.4%)	406 (33.0%)
Survival Status			
Alive	281 (40.3%)	404 (75.8%)	685 (55.6%)
Dead	417 (59.7%)	129 (24.2%)	546 (44.4%)
Cancer-Specific Death			
Alive or Dead of Other Cause	393 (56.3%)	429 (80.5%)	822 (66.8%)
Dead	305 (43.7%)	104 (19.5%)	409 (33.2%)
Survival Months			

Mean (SD)	41.2 (32.2)	17.4 (13.8)	30.9 (28.4)
Median [Min, Max]	34.0 [0, 118]	14.0 [0, 47.0]	21.0 [0, 118]